engleski

Angiogenesis and inhibition.

Angiogenesis leads in formation of blood vessels and may be fisiologic or abnormal. Fisiological angionenesis is esential for vound healing and in embriogenesis. Abnormal angiogenesis is required for a tumor to growth and metastasis and is stimulated by hipoxia in tumor. Angiogenesis is regulated through a balance of pro– and anti-angiogenic factors. Scientiests work to find the best agents that can block the development of blood vessels in tumors and blocade the tumor growth and metastasis. The vascular endothelial growth factor family (VEGF) of ligands and its receptors play a critical role in regulation of fiziologic and abnormal angiogenesis. VEGF enhanced expression in individuals with malignant disease indicates a bad progosis. The cognition of anti-VEGF factors suggest that thay may have therapeutic potential for prevention of tumor growth and metastasis. Anti-angiogenesis drugs act where new blood vessels are forming and this treatment is systemic. Chemotherapy and anti-angiogenesis drugs can be given together as strong attack against cancer. Natural angiogenesis inhibitors endostatin, tumstatin, and thrombospondin-1 can have effect on the progression of tumors. The people with Down syndrome have exceptionally low rates of most kinds of cancer having a 1.7-fold higher level of endostatin in the blood. Protein encoded on chromosome 21, Down syndrome critical region 1 (DSCR-1), can block new blood vessel formation acting as an inhibitor of signaling pathways related to cell growth and migration in endothelial cells. Further investigations of the antiangiogenic pathway and its relation to tumor inhibition is essential and Down syndrome is a good model.

angiogenesis; inhibition

nije evidentirano